Vol. 1 No. 1 (2025), Articles
Vol. 1 No. 1 (2025)

THE USAGE OF CALENDULA AND INULA HELENIUM, WHICH ARE CULTIVATED IN UZBEKISTAN, IN TRADITIONAL MEDICINE FOR GASTROINTESTINAL DISORDERS

Articles
Published 2025-03-29
Ibragim Askarov
Andijan State University, Andijan, Uzbekistan
Khabibullo Kodirov
Andijan Medical Institute, Andijan, Uzbekistan
PDF
DOI

Keywords

calendula, inula helenium, ulcerative colitis.

How to Cite

THE USAGE OF CALENDULA AND INULA HELENIUM, WHICH ARE CULTIVATED IN UZBEKISTAN, IN TRADITIONAL MEDICINE FOR GASTROINTESTINAL DISORDERS (Ibragim Askarov & Khabibullo Kodirov , Trans.). (2025). CANADA - SCIENTIFIC REVIEW OF THE PROBLEMS AND PROSPECTS OF MODERN SCIENCE AND EDUCATION, 1(1), 13-16. https://e-conferences.org/index.php/canada/article/view/17
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Information on ulcerative colitis is given in this article. The article addresses non-specific ulcerative colitis treatment criteria, classification, clinics, and diagnostic methods based on international recommendations. Therapy indications and recommended doses for inula helenium, calendula, achillea, plantago, hypericum, and bidens based on severity stages are given, along with the Truelove/Witts and Mayo score criteria for assessing the severity stages of non-specific ulcerative colitis.                                                              

PDF
DOI

References

1. Андреева Н.С., Реброва О.Ю., Зорин Н.А., Авксентьева М.В., Омельяновский В.В. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная ха- рактеристика и перспективы унификации. Оценка медицинских технологий. 2012;(4). Режим доступа: http://www.hta-rus.ru/magazine-archive/147-istemyi-otsenki-dostovernosti-nauchnyih- dokazatelstv-i-ubeditelnosti-rekomendatsiy-sravnitelnaya.

2. Асқаров И.Р. Табобат қомуси. Т.: "Мумтоз сўз". –2019. –Б. 1142.

3. Асқаров И.Р. Фитотерапия. Дарслик. Тошкент. "Фан ва техналогиялар нашриёт-матбаа уйи". 2023 й.

4. Cosnes J., Gower-Rousseau C., Seksik P., Corkot A. Epidemiology and natural history of inflamma- tory bowel diseases. Gastroenterology. 2011;140(6):1785–1794. doi: 10.1053/j.gastro.2011.01.055.

5. Danese S., D’Amico F., Bonovas S., Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Al- gorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018;24(10):2106–2112. doi: 10.1093/ibd/izy076.

6. D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of re- mission in ulcerative colitis. Aliment Pharmacol Ther. 2016;44(10):1018–1029. doi: 10.1111/apt.13803.

7. Silverberg M.S., Satsangi J., Ahmad T. et al. Toward an integrated clinical, molecular and sero- logical classification of inflammatory bowel disease: report of a Working Party of the 2005 Mon- treal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A–36A. doi: 10.1155/2005/269076.

8. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–1048. doi: 10.1136/bmj.2.4947.1041.

9. Seah D., De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43(4):482–513. doi: 10.1111/apt.13491.

10. Hindryckx P., Jairath V., D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13(11):654–664. doi: 10.1038/nrgastro.2016.116.